In managing non-renal SLE, how do you approach choosing between belimumab and anifrolumab?

Dr. @Dr. First Last, You are asking what we are all dreaming of... personalized medicine where we could identify a patient's immunologic endotype and better choose disease-modifying drugs rather than cycling patients from one combination of drugs to another.

Right now, it is a dream. With so many bio...

This is a complex but important question, and I typically begin by clarifying the organ system involved, the severity of disease, previous treatment history—particularly any failure of conventional DMARDs—and the current steroid burden, as this greatly influences the choice of biologic.

1. Choosing ...